ArticleJornal brasileiro de nefrologia
Current treatment of lupus nephritis: an overview of the new guidelines.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rituximab as Rescue or Add-On Therapy for Relapsing or Refractory Lupus Nephritis: A Systematic Review and Meta-Analysis.Clinical and translational science · 2026Pooled it
- Screening of diagnostic biomarkers for taurine metabolism-related genes in lupus nephritis and analysis of immune infiltration.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGiven the relevance of renal involvement in systemic lupus erythematosus (SLE) and new approaches to the disease and its treatment, this article aimed to synthesize the main updates in the diagnosis, management, and treatment of lupus nephritis (LN), based on recent publications of international reference guidelines in nephrology and rheumatology, in addition to highlighting aspects of interest from the 2024 national guidelines of the Brazilian Society of Rheumatology (SBR). The treatments for each class of lupus nephritis are described, as well as the therapeutic targets, underlining similarities and differences between the guidelines. In general, they recommend that induction ("initial") treatment of proliferative classes be performed with monotherapy using mycophenolate or intravenous cyclophosphamide, or with multitarget regimens, using corticosteroids, mycophenolate or cyclophosphamide, and a calcineurin inhibitor or belimumab as a third drug. A change in therapy should be considered if the expected response target is not achieved, which presents subtle differences among current consensus guidelines. Maintenance ("subsequent") treatment should preferably be performed with mycophenolate, azathioprine, or multi-target therapies. Emerging scientific evidence has provided treatment options that impact the management of lupus nephritis, thereby justifying the publication of new guidelines in recent months. Critically analyzing these guidelines may assist in decision-making for the individualized treatment of individuals with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.